Protease-Activated Contrast Agents for Tumor Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protease-triggered smart probes for tumor imaging have limitations in tumor contrast and are not optimized for use with clinically-approved imaging instrumentation, particularly for imaging multiple tumor types and within existing surgical workflows.
Innovation Solution
Development of novel compounds and compositions that target animal proteases, specifically cathepsin cysteine proteases, using quenched fluorescent substrate probes with a latent lysosomotropic effect to enhance signal retention and duration, compatible with existing clinical instrumentation for improved tumor visualization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If protease-triggered smart probes are used for tumor imaging, then tumor-specific signal activation is achieved, but tumor contrast and signal duration are insufficient
Solution Approach 1:
The probe is designed with a quencher already attached to the fluorophore before administration, creating a pre-assembled inactive complex that only activates upon protease cleavage. This preliminary configuration ensures that the fluorophore remains non-fluorescent during circulation and only generates signal when specifically cleaved by tumor-associated proteases, thereby improving both contrast and signal duration
Solution Approach 2:
The probe combines multiple functional components (fluorophore, quencher, protease substrate sequence, and lysosomotropic moiety) into a single composite molecule. This composite structure allows the probe to exhibit multiple functions: fluorescence generation upon cleavage, tumor-specific targeting, and enhanced retention in tumor tissue through lysosomal accumulation, collectively improving tumor contrast and signal persistence
2Measurement precision
If existing clinical instrumentation is used for tumor imaging, then ease of operation is maintained, but measurement precision and tumor visualization quality are limited
Solution Approach 1:
The probe is designed to emit fluorescence at specific wavelengths that match the detection capabilities of existing clinical imaging systems. By tuning the fluorophore's emission parameters to align with standard clinical instrumentation specifications, the probe achieves high tumor visualization quality while maintaining compatibility with existing surgical workflows and equipment
Solution Approach 2:
The probe design incorporates universal features that enable it to work with multiple types of clinical imaging instrumentation. The fluorophore's spectral properties and the probe's overall design are optimized to be compatible with various detection systems, allowing the same probe to improve tumor visualization quality across different clinical settings without requiring specialized equipment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds provide enhanced cellular uptake and sensitivity, allowing for effective visualization of tumors using existing clinical instrumentation, with improved contrast and prolonged signal duration, facilitating more accurate surgical interventions.
Implementation Method 1
quenched fluorescent substrate probes with a latent lysosomotropic effect to enhance signal retention and duration
Data Source
AI summary
Compounds useful as contrast agents in image-guided surgery are provided. The compounds comprise a latent cationic lysosomotropic fragment that is detectable upon cleavage by lysosomal proteases within treated tissues, particularly within tumors and other diseased tissues. Also provided are compositions comprising the compounds and methods for using the compounds, for example in dynamically monitoring protease activity in vivo during image-guided tumor resection surgery.